Most recently, Smith et al. demonstrated that a novel c-Met and VEGFR dual TKI (cabozantinib) resulted in a partial or complete resolution of bone lesions measured by Tc-99m bone scans and also the improvement of cancer-induced bone pain [33,34]. Here, MET is linked to cancer.